Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322986 | 0.86 | ALDH1A1 (0.66) | TAAR1SIGMAR1ALDH1A1CYP2A13 | |
| SCHEMBL12073194 | 0.84 | ALDH1A1 (0.68) | TAAR1SIGMAR1KCNH2GRM2HTR2A | |
| SCHEMBL3600033 | 0.82 | CXCR4 (0.54) | TAAR1KCNH2HTR2A | |
| SCHEMBL3589864 | 0.81 | MAOA (0.52) | TAAR1SIGMAR1KCNH2GRM2HTR2A | |
| SCHEMBL5781401 | 0.81 | GRM2 (0.50) | TAAR1SIGMAR1KCNH2GRM2HTR2A | |
| SCHEMBL5752361 | 0.81 | SIGMAR1 (0.51) | TAAR1SIGMAR1KCNH2GRM2HTR2A | |
| Methane SCHEMBL3600037 | 0.80 | MAOA (0.51) | TAAR1SIGMAR1KCNH2GRM2HTR2A | |
| SCHEMBL1298794 | 0.80 | SIGMAR1 (0.69) | SIGMAR1ALDH1A1 | |
| SCHEMBL24324268 | 0.80 | TAAR1 (0.62) | TAAR1SIGMAR1KCNH2GRM2HTR2A | |
| SCHEMBL5871946 | 0.79 | GRM2 (0.46) | TAAR1SIGMAR1KCNH2GRM2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | TAAR1 2436/4885SIGMAR1 3622/4885KCNH2 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.